SCHEMBL13420288

SCHEMBL13420288

C[C@H](CCO)[C@H]1CC[C@@]2(C)C3CCC4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 2/20 0.70
ACACA Q13085 2/20 0.70
PTPN11 Q06124 1/20 0.62
HSD11B1 P28845 3/20 0.55
HSD11B2 P80365 1/20 0.55
CRYAB P02511 2/20 0.40
USP2 O75604 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
ACHE P22303 2/20 0.38
HMGCR P04035 1/20 0.38
EBP Q15125 1/20 0.38
CRYAA P02489 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13420286 0.89 ACLY (0.68) ACLYACACAPTPN11HSD11B1HSD11B2
Cycloartanol SCHEMBL1881616 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL12634185 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
SCHEMBL29510985 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
Cycloartanol SCHEMBL455049 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
Cycloartanol SCHEMBL12152356 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
Cycloartanol SCHEMBL13801860 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
Cycloartanol SCHEMBL13324286 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
Cycloartanol SCHEMBL455050 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2
Cycloartanol SCHEMBL1881613 0.88 ACLY (0.67) ACLYACACAPTPN11HSD11B1HSD11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283217-A1 MODULATORS OF AMYLOID-BETA PRODUCTION SATORI PHARMACEUTICALS, INC. (US) 2012-11-08 US disclosed
US-20100056487-A1 MODULATORS OF AMYLOID-BETA PRODUCTION SATORI PHARMACEUTICALS, INC. (US) 2010-03-04 US disclosed
WO-2008130449-A2 MODULATORS OF AMYLOID-BETA PRODUCTION SATORI PHARMACEUTICALS, INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283217-A1 MODULATORS OF AMYLOID-BETA PRODUCTION APP, BACE1, BACE2 ACLY 668/4885ACACA 195/4885PTPN11 4386/4885
US-20100056487-A1 MODULATORS OF AMYLOID-BETA PRODUCTION APP, BACE1, BACE2 ACLY 668/4885ACACA 195/4885PTPN11 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.